Dr Reddy's To Market Amgen Therapies In India
This article was originally published in Scrip
Dr Reddy's Laboratories is to market and distribute three Amgen therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) on the Indian market.
You may also be interested in...
Amgen is building on its alliance with Dr. Reddy’s Laboratories in India, shifting out certain products previously sold by GlaxoSmithKline in the country to the Hyderabad-based firm.
Amgen's PCSK9 inhibitor Repatha, already constrained by payor pushbacks on prices in the West and awaiting outcomes data, now appears to be facing a challenge in India. A key Indian expert panel has turned down Amgen's request for a trial waiver for evolocumab, a move that could hold up launch plans with partner Dr Reddy's.
Dr Reddy’s is to press ahead with India filing plans for single-dose COVID-19 vaccine Sputnik Light and also expects to “build on” the Russian partner’s trial in adolescents of the two-dose Sputnik V. The company also pilots a partnered first-of-its-kind cashless digital health offering.